TheDigger Intelligence Unit
The US Food and Drug Administration has approved the first mRNA-based flu vaccine in the country, giving adults aged 50 and above a new immunisation option ahead of the 2026–2027 flu season.
The vaccine, named mFlusiva and developed by Moderna, received full approval for adults aged 50 to 64, and accelerated approval for those 65 and older, with the company required to complete an additional study confirming its clinical benefit in that older age group. Infectious disease specialists have described the approval as significant, not only for giving patients another choice, but for introducing a more responsive vaccine-development approach to flu prevention generally. Moderna is separately studying the vaccine in younger age groups, though further data will be needed before the FDA can consider expanding approval to them.
Why an mRNA approach matters
Traditional flu vaccines are typically grown in chicken eggs, a manufacturing process that can take six months or longer, forcing vaccine makers to select which viral strains to target long before flu season begins, often based on strain data from the Southern Hemisphere’s earlier flu season. mFlusiva instead uses lab-made messenger RNA that instructs the body’s cells to produce proteins matching those found on the surface of targeted flu viruses, training the immune system to recognise and respond to the real virus later.
The principal advantage is speed: Moderna says mFlusiva can move from strain selection to production in roughly two to three months, compared with about six months for conventional flu vaccines. That shorter timeline allows manufacturers to select strains closer to the start of flu season, reducing the risk of a mismatch between the vaccine and the strains actually circulating once flu season arrives — a recurring limitation of egg-based vaccine production.
Trial results
The FDA’s approval for adults aged 50 to 64 was based on a late-stage trial involving more than 40,000 adults across 11 countries, in which mFlusiva proved roughly 27 percent more effective than a standard-dose flu vaccine at preventing laboratory-confirmed influenza in adults 50 and older. Accelerated approval for adults 65 and older rested largely on a separate study of nearly 3,000 adults, which found the vaccine produced a strong immune response comparable to that of an existing high-dose flu vaccine for older adults.
No new safety concerns were identified during review. Common reactions reported included injection-site pain, fatigue, headache, muscle and joint pain, chills, nausea and fever — broadly consistent with reactions seen with other flu vaccines.
A bumpy regulatory path
The approval followed an unusual reversal by the FDA. Earlier this year, the agency declined to accept Moderna’s initial application for review, citing concerns that the company’s large trial had compared mFlusiva against a standard-dose flu shot in adults 65 and older rather than a more appropriate comparator. Moderna pushed back, noting that FDA staff had previously agreed to that trial design, and pointed to its separate study comparing the vaccine with a high-dose option in older adults.
The FDA subsequently agreed to review a revised application, ultimately granting full approval for the 50-to-64 age group and accelerated approval for those 65 and older, pending additional research. In June, the agency’s independent vaccine advisory committee unanimously recommended approval for both groups — an outcome one infectious disease specialist at Yale School of Medicine described as a remarkable and rapid reversal from the agency’s position only months earlier.
What the 2026–2027 flu shots will target
mFlusiva adds to, rather than replaces, the existing range of flu vaccines available this season, which also include updated standard-dose inactivated shots, high-dose and adjuvanted formulations for older adults, and the FluMist nasal spray. All US flu vaccines for the coming season are formulated to protect against three viruses: an influenza A(H1N1) strain, an A(H3N2) strain, and a B/Victoria-lineage strain, each updated since the previous season, including changes intended to improve protection against the H3N2 subclade K virus that circulated widely during the 2025–2026 season. Experts note it remains too early to gauge how severe the coming Northern Hemisphere flu season will be, though early Southern Hemisphere data suggest H3N2 is currently predominant, with influenza B cases on the rise.
Availability and timing
Other flu vaccine brands have already begun arriving at pharmacies, and Moderna says mFlusiva is expected to reach select retailers within the coming weeks. One complicating factor: the US Centres for Disease Control and Prevention’s vaccine advisory committee has not yet formally recommended mFlusiva and is currently unable to meet due to a federal court order, a situation that could affect insurance coverage even though the vaccine is legally approved for use.
Health experts generally recommend getting a flu vaccine in October, timed so protection remains strong through the typical December-to-January peak and into spring, consistent with CDC guidance identifying September and October as the optimal vaccination window for most people. Specialists note that timing can shift based on individual circumstances such as travel, but advise getting vaccinated well before the Thanksgiving period regardless of which vaccine is chosen.
Source: Reporting based on Everyday Health (Becky Upham, published August 7, 2026), citing FDA approval documentation, Moderna clinical trial data, and commentary from infectious disease specialists at UW Medicine, UNC Chapel Hill and Yale School of Medicine.
